WO2005035746A3 - Medical use of tbk-1 or of inhibitors thereof - Google Patents

Medical use of tbk-1 or of inhibitors thereof Download PDF

Info

Publication number
WO2005035746A3
WO2005035746A3 PCT/EP2004/010996 EP2004010996W WO2005035746A3 WO 2005035746 A3 WO2005035746 A3 WO 2005035746A3 EP 2004010996 W EP2004010996 W EP 2004010996W WO 2005035746 A3 WO2005035746 A3 WO 2005035746A3
Authority
WO
WIPO (PCT)
Prior art keywords
tbk
inhibitors
medical use
pharmaceutical
well
Prior art date
Application number
PCT/EP2004/010996
Other languages
French (fr)
Other versions
WO2005035746A2 (en
Inventor
Christian Korherr
Original Assignee
Xantos Biomedicine Ag
Christian Korherr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xantos Biomedicine Ag, Christian Korherr filed Critical Xantos Biomedicine Ag
Priority to US10/574,306 priority Critical patent/US20070149469A1/en
Priority to EP04765755A priority patent/EP1670908A2/en
Priority to CA002540775A priority patent/CA2540775A1/en
Publication of WO2005035746A2 publication Critical patent/WO2005035746A2/en
Publication of WO2005035746A3 publication Critical patent/WO2005035746A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel angiogenic factor, TBK-1, we well as to inhibitors thereof and to their use in pharmaceutical or diagnostic compositions.
PCT/EP2004/010996 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof WO2005035746A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/574,306 US20070149469A1 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof
EP04765755A EP1670908A2 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof
CA002540775A CA2540775A1 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810003P 2003-10-02 2003-10-02
US60/508,100 2003-10-02

Publications (2)

Publication Number Publication Date
WO2005035746A2 WO2005035746A2 (en) 2005-04-21
WO2005035746A3 true WO2005035746A3 (en) 2005-06-23

Family

ID=34434896

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2004/010994 WO2005034978A2 (en) 2003-10-02 2004-10-01 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
PCT/EP2004/010996 WO2005035746A2 (en) 2003-10-02 2004-10-01 Medical use of tbk-1 or of inhibitors thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010994 WO2005034978A2 (en) 2003-10-02 2004-10-01 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF

Country Status (3)

Country Link
EP (1) EP1670908A2 (en)
CA (1) CA2540775A1 (en)
WO (2) WO2005034978A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304736A (en) * 2005-09-07 2008-11-12 雪兰诺实验室公司 IKK inhibitors for the treatment of endometriosis
CA2767914C (en) * 2009-07-24 2020-02-25 Geadic Biotec, Aie. Markers for endometrial cancer
GB201114051D0 (en) * 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
US10370664B2 (en) * 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039410A1 (en) * 1997-03-07 1998-09-11 Tularik Inc. IλB $i(KINASES)
WO1999058558A2 (en) * 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Cell signaling proteins
WO2000008179A1 (en) * 1998-08-04 2000-02-17 Immunex Corporation Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases
WO2001044444A2 (en) * 1999-12-14 2001-06-21 Glaxo Wellcome Kabushiki Kaisha A protein kinase (ikk4) involved in the phosphorylation of ikb
US20030232771A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of MARK3 expression
WO2004012673A2 (en) * 2002-08-01 2004-02-12 Wyeth, Methods and reagents relating to inflammation and apoptosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US20030050270A1 (en) * 1998-11-20 2003-03-13 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-beta expression
GB9828704D0 (en) * 1998-12-24 1999-02-17 Nippon Glaxo Limited Proteins
AU2126502A (en) * 2000-10-03 2002-04-15 Gene Logic, Inc. Gene expression profiles in granulocytic cells
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2004001008A2 (en) * 2002-06-21 2003-12-31 Incyte Corporation Kinases and phosphatases
WO2004097009A2 (en) * 2003-05-01 2004-11-11 Novartis Ag METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039410A1 (en) * 1997-03-07 1998-09-11 Tularik Inc. IλB $i(KINASES)
WO1999058558A2 (en) * 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Cell signaling proteins
WO2000008179A1 (en) * 1998-08-04 2000-02-17 Immunex Corporation Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases
WO2001044444A2 (en) * 1999-12-14 2001-06-21 Glaxo Wellcome Kabushiki Kaisha A protein kinase (ikk4) involved in the phosphorylation of ikb
US20030232771A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of MARK3 expression
WO2004012673A2 (en) * 2002-08-01 2004-02-12 Wyeth, Methods and reagents relating to inflammation and apoptosis

Also Published As

Publication number Publication date
EP1670908A2 (en) 2006-06-21
WO2005034978A3 (en) 2005-06-23
WO2005035746A2 (en) 2005-04-21
WO2005034978A2 (en) 2005-04-21
CA2540775A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP2415760A3 (en) CCR-9 antagonists
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2009074735A8 (en) Use of a novel natural agent in cosmetic compositions
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2004041269A3 (en) New use for pharmaceutical composition
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
EP2540301A3 (en) Methods and pharmaceutical compositions for healing wounds
ITMI20031570A1 (en) COMPOSITION FOR DIETARY, PHARMACEUTICAL OR COSMETIC USE
WO2006034001A3 (en) Methods of treating hiv infection
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
NO20054346L (en) Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions
ITRM20030363A0 (en) COMPOSITIONS INCLUDING 3, 5DIIODOTYRONINE AND DIESSE PHARMACEUTICAL USE.
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2006110185A3 (en) Antiinfective lipopeptides
WO2006055663A3 (en) The use of novel antibacterial compounds
WO2005035746A3 (en) Medical use of tbk-1 or of inhibitors thereof
WO2006103119A3 (en) Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2540775

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006530070

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004765755

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004765755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007149469

Country of ref document: US

Ref document number: 10574306

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10574306

Country of ref document: US